Skip to main content
. Author manuscript; available in PMC: 2021 Jul 5.
Published in final edited form as: Biomater Sci. 2021 Mar 10;9(5):1668–1682. doi: 10.1039/d0bm01728k

Figure 2. Circulating Immune Cell Populations.

Figure 2.

Circulating immune cell populations at baseline prior to defect creation, and at Week 0 prior to BMP-2 treatment (8 weeks post-defect creation) for the bone only defect group and the composite defect group. Significance was determined using one-way ANOVA with p<0.01 (**), p<0.005 (***), and p<0.001 (****).